OraSure Technologies, Inc. (OSUR)

Market Cap	243.46M +32.0%
Revenue (ttm)	112.41M -18.9%
Net Income	-49.13M
EPS	-0.69
Shares Out	68.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	745,344
Open	3.500
Previous Close	3.440
Day's Range	3.420 - 3.620
52-Week Range	2.080 - 4.580
Beta	1.06
Analysts	Buy
Price Target	5.50 (+55.81%)
Earnings Date	Nov 9, 2026

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid tes...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 12, 1986
• Employees: 500
• Stock Exchange: Nasdaq
• Ticker Symbol: OSUR
• Website: https://www.orasure.com

Financial Performance

In 2025, OraSure Technologies's revenue was $115.02 million, a decrease of -38.10% compared to the previous year's $185.83 million. Losses were -$68.73 million, 252.5% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 55.81% from the latest price.

Price Target

$5.5

(55.81% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 10, 2026

Data Sources Report a data error